Matt WolfeFutureTools.io · Founder of Future Tools | Host of Next Wave Podcast

OpenAI Wants A Cut Of ChatGPT Drug Discoveries

26 Jan 2026 · 1 min

Watch on YouTube

0:49

This content was created by Matt Wolfe. This content was uploaded by Matt Wolfe. This is a YouTube video titled "OpenAI Wants A Cut Of ChatGPT Drug Discoveries" (created 2026-01-26T13:30:00Z). The excerpt is a spoken commentary by a single unnamed speaker (labeled SPEAKER A) summarizing reporting that OpenAI’s CFO indicated the company may seek licensing rights, IP-based agreements, or outcome-based pricing to capture value from AI-aided drug discoveries. The speaker also notes that rivals — Anthropic, Google/DeepMind, and Isomorphic Labs — are exploring similar partnerships and data-licensing arrangements with biotech startups. The content reads like news/commentary rather than a multi-person conversation.

Chapters

If you're using an AI model and that model helps you discover a brand new drug, well, OpenAI wants a piece of that. Apparently they're planning to take a cut of customers AI aided discoveries. So what does that mean? Here's what The CFO of OpenAI said her company could for instance, take license to the drugs that it discovered. In an article, the CFO also said licensing, IP based agreements and outcome based pricing will share in the value created. Now, to be fair to OpenAI, they're not the only one who is thinking about about doing this. They just kind of have been the most public about it recently. According to this article on the information here, it says its rivals, anthropic Google, DeepMind and isomorphic labs are focusing on using AI for drug discovery and have also held discussions with early stage biotechnology startups about data licensing and partnerships.